Parkinson's Disease Clinical Trial
Official title:
Role of Mesocorticolimbic Pathway in Apathy of Patients With Parkinson's Disease. - Study Using Diffusion Tensor Imaging and Fibres Tracking
Use lay language.
Apathy is one of the most under recognised, underdiagnosed and poorly managed aspects of
Parkinson's disease. Depending on methodological approach of the study, its prevalence is
estimated to be between 16 and 51%.
Apathy derives from a dysfunction of the dopaminergic meso cortico limbic systems, which
seems to play a central role in the control of mood and motivation. The subcortical
components of this system are the ventral tegmental area (VTA), the nucleus accumbens, and
the constituents of the limbic system (particularly the hippocampus and amygdala), all of
which are located deep inside the brain (18). The hypothesis is that depletion of striatal
dopamine from regulators located in the midbrain (VTA and SNpc) in striato-thalamo-cortical
circuits results in hypofunction of these circuits and the loss of frontal cortical
activity, particularly within in the frontal orbital cortex, the anterior cingulate cortex
and the prefrontal cortex
The objective of this study is to explore, using diffusion weighted MRI, the regions of the
brain which are proposed to play a role in motivation in apathetic Parkinson's disease
patients and to define more precisely the relation between dopaminergic fibres and the
meso-cortico-limbic system with the help of tractography methods
3 groups :
- 20 apathetic patients with Parkinson's disease
- 20 non apathetic paired patients)
- 20 healthy paired control
Description of the protocol for patients :
J0 : Inclusion visit (duration : 4h):
- motor assessment (UPDRS)
- neuropsychological and psychiatric assessment : Cognitive assessments : Mini Mental
State MMS, MATTIS Apathy assessment: Apathy Inventory from Robert et al (2002); Lille
apathy rating scale (LARS) ; Starkstein scale.
Depression assessment : Montgomery et Alsberg depression rating scale (MADRS)
J0+1 day : MRI (magnetic resonance imaging) acquisition (30 minutes) Multimodal MRI
examinations will be performed (Diffusion-weighted data and high-resolution 3-dimensional
(3D) T1- weighted as well as T2-weighted images) on each subject on a GE 3-T.
;
Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02915848 -
Long-term Stability of LFP Recorded From the STN and the Effects of DBS
|
||
Recruiting |
NCT03648905 -
Clinical Laboratory Evaluation of Chronic Autonomic Failure
|
||
Terminated |
NCT02688465 -
Effect of an Apomorphine Pump on the Quality of Sleep in Parkinson's Disease Patients (POMPRENELLE).
|
Phase 4 | |
Completed |
NCT05040048 -
Taxonomy of Neurodegenerative Diseases : Observational Study in Alzheimer's Disease and Parkinson's Disease
|
||
Active, not recruiting |
NCT04006210 -
Efficacy, Safety and Tolerability Study of ND0612 vs. Oral Immediate Release Levodopa/Carbidopa (IR-LD/CD) in Subjects With Parkinson's Disease Experiencing Motor Fluctuations
|
Phase 3 | |
Completed |
NCT02562768 -
A Study of LY3154207 in Healthy Participants and Participants With Parkinson's Disease
|
Phase 1 | |
Completed |
NCT00105508 -
Sarizotan HC1 in Patients With Parkinson's Disease Suffering From Treatment-associated Dyskinesia
|
Phase 3 | |
Completed |
NCT00105521 -
Sarizotan in Participants With Parkinson's Disease Suffering From Treatment Associated Dyskinesia
|
Phase 3 | |
Recruiting |
NCT06002581 -
Repetitive Transcranial Magnetic Stimulation(rTMS) Regulating Slow-wave to Delay the Progression of Parkinson's Disease
|
N/A | |
Completed |
NCT02236260 -
Evaluation of the Benefit Provided by Acupuncture During a Surgery of Deep Brain Stimulation
|
N/A | |
Completed |
NCT00529724 -
Body Weight Gain, Parkinson, Subthalamic Stimulation
|
Phase 2 | |
Active, not recruiting |
NCT05699460 -
Pre-Gene Therapy Study in Parkinson's Disease and Multiple System Atrophy
|
||
Completed |
NCT03703570 -
A Study of KW-6356 in Patients With Parkinson's Disease on Treatment With Levodopa-containing Preparations
|
Phase 2 | |
Completed |
NCT03462680 -
GPR109A and Parkinson's Disease: Role of Niacin in Outcome Measures
|
N/A | |
Completed |
NCT02837172 -
Diagnosis of PD and PD Progression Using DWI
|
||
Not yet recruiting |
NCT04046276 -
Intensity of Aerobic Training and Neuroprotection in Parkinson's Disease
|
N/A | |
Recruiting |
NCT02952391 -
Assessing Cholinergic Innervation in Parkinson's Disease Using the PET Imaging Marker [18F]Fluoroethoxybenzovesamicol
|
N/A | |
Active, not recruiting |
NCT02937324 -
The CloudUPDRS Smartphone Software in Parkinson's Study.
|
N/A | |
Completed |
NCT02927691 -
Novel Management of Airway Protection in Parkinson's Disease: A Clinical Trial
|
Phase 2 | |
Completed |
NCT02939391 -
A Study of KW-6356 in Subjects With Early Parkinson's Disease
|
Phase 2 |